Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer

J Cell Biochem. 2019 Jan;120(1):105-114. doi: 10.1002/jcb.27130. Epub 2018 Sep 14.

Abstract

The correlation between lung cancer tumor markers and sex differences in lung cancer remains a clinical problem that is worthy of further study. This study investigated the significance of the combined detection of 17β-estrogen (E2) and tumor markers in the diagnosis and prognosis of lung cancer. A total of 174 patients, including 117 patients with non-small-cell lung cancer (NSCLC) and 57 patients with benign pulmonary lesions (BPL), were enrolled. An enzyme-linked immunosorbent assay was used to detect the expression of E2, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) in patients with NSCLC and BPL to analyze the correlation between E2 and CEA, NSE or CYFRA21-1 expression, and its correlation with clinicopathological features and prognosis. The expression of tumor markers was then examined in different lung cancer cells (A549, H1795, H460, and SK-MES-1). The expression of tumor markers was detected by a real-time reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analysis. The expressions of p-p44/42 mitogen-activated protein kinase (MAPK) and phospho-AKT (p-AKT) were detected by Western blot analysis. The expression levels of E2, CEA, NSE, and CYFRA21-1 in patients with NSCLC were significantly higher than those in patients with BPL ( P < .05); E2 was positively correlated with tumor markers ( P < .01). Patients with a high expression of E2 and tumor markers showed a poor prognosis ( P < .05). RT-quantitative PCR and Western blot analysis showed that the expression levels of CEA, NSE, CYFRA21-1, p-p44/42 MAPK, and p-AKT in the E2 group were higher than those in the other groups ( P < .05). These studies indicate that the interaction of E2 and tumor markers can significantly improve the role of tumor markers in the diagnosis and prognosis of lung cancer.

Keywords: carcinoembryonic antigen; enzyme-linked immunosorbent assay; neuron-specific enolase, 17β-estrogen; non-small-cell lung cancer.

MeSH terms

  • A549 Cells
  • Antigens, Neoplasm / blood*
  • Biomarkers, Tumor / blood
  • Blotting, Western
  • Carcinoembryonic Antigen / blood*
  • Carcinoma, Non-Small-Cell Lung / blood*
  • Carcinoma, Non-Small-Cell Lung / diagnosis
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Squamous Cell / blood
  • Enzyme-Linked Immunosorbent Assay
  • Estrogens / blood*
  • Estrogens / pharmacology
  • Female
  • GPI-Linked Proteins / blood
  • Humans
  • Keratin-19 / blood*
  • Lung Neoplasms / blood*
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Menopause
  • Middle Aged
  • Mitogen-Activated Protein Kinases / metabolism*
  • Phosphopyruvate Hydratase / blood*
  • Prognosis
  • Proto-Oncogene Proteins c-akt / metabolism*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction / drug effects
  • Survival Rate

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • CEACAM5 protein, human
  • Carcinoembryonic Antigen
  • Estrogens
  • GPI-Linked Proteins
  • Keratin-19
  • antigen CYFRA21.1
  • Proto-Oncogene Proteins c-akt
  • Mitogen-Activated Protein Kinases
  • Phosphopyruvate Hydratase